Bio-Rad Laboratories (BIO.B) vs Tandem Diabetes Care (TNDM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bio-Rad Laboratories (BIO.B) has outperformed Tandem Diabetes Care (TNDM) over the past year, gaining 28.2% versus a gain of 2.2%. Over five years, BIO.B leads with a -50.5% price change compared with -87.5% for TNDM. Bio-Rad Laboratories is the larger company by market cap ($9.76 billion vs $1.10 billion), about 8.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO.B | TNDM |
|---|---|---|
| Share price | $365.08 | $15.87 |
| Market cap | $9.76B | $1.10B |
| 1-day change | 0.00% | +1.24% |
| YTD return | +17.50% | -28.69% |
| 1-year return | +28.15% | +2.18% |
| 5-year return | -50.54% | -87.50% |
| P/E ratio (TTM) | 46.27 | — |
| Forward P/E | — | 99.84 |
| EPS (TTM) | $7.89 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.58B | — |
| Revenue growth (YoY) | +0.65% | — |
| Net income (latest FY) | $759.90M | — |
| Gross margin | 51.87% | — |
| Operating margin | 1.83% | — |
| Net margin | 29.42% | — |
| 52-week high | $365.08 | $29.65 |
| 52-week low | $244.54 | $12.26 |
| Distance from 52-week high | 0.00% | -46.48% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +75.55% |
| Average volume | 6 | 2.01M |
| Shares outstanding | 5.06M | 69.58M |
| Employees | 7,450 | 2,500 |
| Sector | Healthcare | Health Care |
| Industry | Medical Devices | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bio-Rad Laboratories is about 8.8 times larger than Tandem Diabetes Care by market value ($9.76B vs $1.10B).
- BIO.B has outperformed TNDM by 26.0 percentage points over the past year.
- The two companies sit in different sectors: Bio-Rad Laboratories in Healthcare and Tandem Diabetes Care in Health Care.
About Bio-Rad Laboratories
BIO.B stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Healthcare · Medical Devices · 7,450 employees
About Tandem Diabetes Care
TNDM stock →Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally.
Health Care · Medical/Dental Instruments · 2,500 employees
BIO.B vs TNDM FAQ
Which is bigger, Bio-Rad Laboratories or Tandem Diabetes Care?
Bio-Rad Laboratories (BIO.B) is larger, with a market capitalization of $9.76B compared with $1.10B for Tandem Diabetes Care (TNDM).
Which stock has performed better over the past year, BIO.B or TNDM?
BIO.B returned +28.15% over the past 12 months, compared with +2.18% for TNDM (price return, excluding dividends). Past performance does not predict future results.
Are Bio-Rad Laboratories and Tandem Diabetes Care in the same industry?
No. Bio-Rad Laboratories is in the Healthcare sector, while Tandem Diabetes Care is in Health Care.